Clinical correlation of striatal 1H MRS changes in Huntington's disease

Neurology

Volumn 53, Issue 4, 1999, Pages 806-812

  Sanchez Pernaute R ^a,d   Garcia Segura J M ^b,c   Del Barrio Alba, A ^a   Viano J ^b   De Yebenes J G ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Neuroradiology Unit   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Huntington's disease; Proton MRS; Striatum

Indexed keywords

ADULT; ARTICLE; BRAIN METABOLISM; BRAIN SCINTISCANNING; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; MOTOR PERFORMANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RATING SCALE;

EID: 0033546998     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.4.806     Document Type: Article

References (40)

1. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is unstable in Huntington's disease chromosomes. Cell 1993;72:971-983.
2. Sharp AH, Ross CA. Neurobiology of HD. Neurobiol Dis 1996; 3:3-15.
3. Young AB. Impairment of energy metabolism and excitotoxic cell death in Huntington's disease. Rev Neurol (Paris) 1997; 153:496-498.
4. Brouillet E, Hantraye P, Ferrante RJ, et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 1995;92:7105-7109.
5. Burns LH, Pakzaban P, Deacon TW, et al. Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease. Neuroscience 1995;64: 1007-1017.
6. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AHV. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 1996;39:385-389.
7. Brownne SE, Bowling AC, MacGarvey U, et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 1997; 41:646-653.
8. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR. Evidence for an energy metabolism defect in Huntington's disease using localized proton spectroscopy. Neurology 1993;43:2689-2695.
9. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997;41:160-165.
10. Jenkins BG, Rosas HD, Chen Y-CI, et al. 1H NMR spectroscopy studies of Huntington's disease. Correlations with CAG repeat numbers. Neurology 1998;50:1357-1365.
11. Taylor-Robinson SD, Weeks RA, et al. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the excitotoxic theory? Mov Disord 1996;11:167-173.
12. Shoulson I, Fahn S. Huntington's disease: clinical care and evaluation. Neurology 1979;29:1-3.
13. Benítez J, Fernández E, García Ruíz PJ, Ramos C, García Yébenes J. Trinucleotide (CAG) repeat expansion in chromosomes of Spanish patients with Huntington's disease. Hum Genet 1994;94:563-564.
14. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11: 136-142.
15. Vitte E, Semont A. Assessment of vestibular function by videonystagmoscopy. J Vestib Res 1995;5:377-383.
16. Quinn N, Brown R, Craufurd D, et al. Core Assessment Program for Intracerebral Transplantation in Huntington's Disease (CAPIT-HD). Mov Disord 1996;11:1443-1150.
17. Benton AL, Hamsher K de S. Multilingual aphasia examination. Iowa City, IA: University of Iowa Press, 1978.
18. Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271-276.
19. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643-662.
20. Smith A. The Symbol Digit Modalities Test: a neuropsychological test for economic screening of learning and other cerebral disorders. Learn Disord 1968;3:83-91.
21. Folstein MF, Folstein SE, MacHugh PR. Mini mental state: a practical guide for grading the mental state of the patient for the clinician. J Psychiatr Res 1975;12:189-198.
22. Barr A, Heinze W, Dobben G, Valvassori G, Sugar O. Bicaudate index in computerized tomography of Huntington's disease and cerebral atrophy. Neurology 1978;28:1196-1200.
23. Aylward EH, Schwartz J, Machlin S, Pearlson G. Bicaudate ratio as a measure of caudate volume on MR images. AJNR Am J Neuroradiol 1991;12:1217-1222.
24. Webb PG, Sailasuta N, Kohler SJ, Raidy T, Moats RA, Hurd RE. Automated single-voxel proton MRS: technical development and multisite verification. Magn Reson Med 1994;31: 365-373.
25. Klose U. In vivo proton spectroscopy in the presence of eddy currents. Magn Reson Med 1990;14:26-36.
26. Christiansen P, Henriksen O, Stubgaard M, Gideon P, Larsson HBW. In vivo quantification of brain metabolites by 1H-MRS using water as an internal standard. Magn Reson Imaging 1993;2:107-118.
27. Penney JB, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689-692.
28. Ende G, Laxer KD, Knowlton RC, Matson GB, Schuff N, Weiner MW. Temporal lobe epilepsy: bilateral hippocampal metabolite changes revealed at proton MR spectroscopic imaging. Radiology 1997;202:809-817.
29. Aylward EH, Brandt J, Codori A, Mangus R, Barta PE, Harris G. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 1994;44:823-828.
30. Aylward EH, Codori AM, Barta PE, Pearlson GD, Harris GJ, Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 1996;53: 1293-1296.
31. Aylward EH, Li Q, Stine OC, et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997;48:394-399.
32. Harris GJ, Aylward EH, Peyser CE, et al. Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease. Arch Neurol 1996;53:316-324.
33. Davies SW, Turmaine M, Cozens BA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997; 90:537-548.
34. Becher MW, Kotzuk JA, Sharp AH, et al. Intranuclear neuronal inclusions in Huntington's disease and dentatorubro and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis 1998;4:387-397.
35. Duyao M, Ambrose C, Myers R, et al. Trinucleotide repeat length instability and age at onset in Huntington's disease. Nat Genet 1993;4:387-392.
36. Furtado S, Suchowersky O, Rewcastle NB, Graham L, Klimek ML, Garber A. Relationship between trinucleotide repeat and neuropathological changes in Huntington's disease. Arm Neurol 1996;39:132-136.
37. 11C]Raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol 1998;43: 253-255.
38. Tabrizi SJ, Cleeter MWJ, Xuereb J, Taanman J-W, Cooper JM, Schapira AHV. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 1999;45: 25-32.
39. Grafton ST, Mazziotta JC, Pahl JJ, et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch Neurol 1992;49:1161-1167.
40. Bäckman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain 1997; 120:2207-2217.